论文部分内容阅读
To evaluate platelet aggregation in patients with retinal vein occlusion (RVO) by the light scattering method and compare the effects of three antiplatelet d rugs on aggregate formation. Prospective, nonrandomized, interventional clinical trial. (1) Platelet aggregation was measured in 42 patients with untreated bran ch RVO (BRVO), 26 patients with central RVO (CRVO), and 30 healthy control subjects using a light scatte ring platelet aggregometer. Platelet aggregates were classified as small, medium , and large according to light intensity. Total light intensities of each aggreg ate size were compared between BR VO, CRVO, and control subjects. (2) In 33 pat ients with RVO, platelet aggregation before and 2 weeks after the administration of ticlopidine, beraprost, or aspirin were compared. (1) There was a statistica lly significant difference (P=0.007 3) between the control subjects (8.3×106 a. u.) and CRVO patients (22.9×.106 a.u.) with respect to small aggregates. There was no statistically significant difference with respect to medium and large agg regate formation between the control subjects and either patient group. (2) Comp ared with aggregates formed in the absence of antiplatelet drugs, ticlopidine si gnificantly inhibited only the formation of small aggregates and beraprost that of all sizes; aspirin did not significantly inhibit the formation of any aggrega te sizes. Increase in small platelet aggregates may be attributable to RVO patho genesis. Beraprost and ticlopidine appear to inhibit small aggregate formation i n RVO patients and may represent effective antiplatelet treatments. The lightsca ttering method is useful to investigate the pathogenesis of RVO and the effects of antiplatelet drugs.
To evaluate platelet aggregation in patients with retinal vein occlusion (RVO) by the light scattering method and compare the effects of three antiplatelet d rugs on aggregate formation. Prospective, nonrandomized, interventional clinical trial. (1) Platelet aggregation was measured in 42 patients with untreated bran ch RVO (BRVO), 26 patients with central RVO (CRVO), and 30 healthy control subjects using a light scatter ring platelet aggregometer. Platelet aggregates were classified as small, medium, and large according to light intensity. Total light intensities of (2) In 33 pat ients with RVO, platelet aggregation before and 2 weeks after the administration of ticlopidine, beraprost, or aspirin were compared. (1) There was There was no statia (22.9 × .106 au) with respect to small aggregates. There was no stati ... (a = 0.007 3) between the control subjects (8.3 × 106 au) and CRVO patients stally significant difference with respect to medium and large agg regate formation between the control subjects and either patient group. (2) Comp ared with aggregates formed in the absence of antiplatelet drugs, ticlopidine si gnificantly inhibited only the formation of small aggregates and beraprost that of all sizes; aspirin did not significantly inhibit the formation of any aggrega te sizes. Increase in small platelet aggregates may be attributable to RVO pathogenesis. Beraprost and ticlopidine appear to inhibit small aggregate formation in RVO patients and may represent effective antiplatelet treatments. The lightsca ttering method is useful to investigate the pathogenesis of RVO and the effects of antiplatelet drugs.